RxDoctor Payments Data

Kirsten Shively, PA

Physician Assistant · Walker, MINPI 1700989605

Payments from drug & device makers

$11,054in general payments, 2019–2025

Across 484 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$903
  • GSK$808
  • Pfizer$781
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$90%
  • Food & beverage$10,96499%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,054 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$11,768
Medicare patients
117
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol13$12,096
Albuterol Sulfate HfaAlbuterol Sulfate43$1,450
PaxlovidNirmatrelvir/Ritonavir16$1,429
Atorvastatin Calcium33$735
Levothyroxine Sodium36$646
CefuroximeCefuroxime Axetil61$607
Fluticasone Propionate20$374
Rosuvastatin Calcium11$231
Losartan Potassium12$215
Alendronate Sodium19$212
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst25$206
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav26$171
Omeprazole15$168
Doxycycline Monohydrate23$111
Ondansetron OdtOndansetron13$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,103$12,09613 claims
PfizerPaxlovid$781$1,42916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Walker

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →